Navigation Links
Revenue Growth Optimism in Pharmaceutical Industry: 2013 Survey Reports at RnRMarketResearch.com
Date:2/19/2013

DALLAS, Feb. 19, 2013 /PRNewswire-iReach/ -- Overall, as per the global pharmaceutical industry survey on buyer spend and procurement strategies, 55% of respondents are 'more optimistic' about revenue growth for their companies in 2013, due to success in clinical trials, approval and acceptance from drug authorities, an increase in expenditure from governments and a surge in sales, all of which are projected to increase the profitability of pharmaceutical manufacturing companies in 2013. The top three key expected changes for 2013 are development of new products and services, improvement of operational efficiency and 'expansion in current markets'.

(Photo: http://photos.prnewswire.com/prnh/20130219/CG62209)

Among emerging markets, China is identified as the most important region for pharmaceutical industry growth, along with Brazil and India. Presence of huge and aging population, economic development, growing public expenditure towards healthcare, government support, increasing awareness about health and fitness in public are key drivers for the growth of the pharmaceutical market in China.

Developed pharmaceutical markets such as Singapore, Taiwan, Hong Kong, the US, and South Korea are also identified as important regions for growth in 2013. The availability of a skilled workforce and the presence of logistics support, which increases connectivity to target markets within the region, positions Singapore as a strategically important link within the South-East Asia region. Moreover, Singapore acts as a significant trading base for the South-East Asian region, with low corporate taxes and strong intellectual property rights attracting companies to setup their operations in Singapore. The world's largest pharmaceutical market, the US, is expected to register minimal growth over the next five years; however, beyond 2015, a higher number of people will be insured in the US, resulting in increased drug consumption.

Executives from the global pharmaceutical industry expect to see increased levels of consolidation, with 61% of respondents anticipating either a significant increase or an increase in M&A activity in 2013. The need for new product pipelines, new product acquisition, patent expiries, cost containment, and credit availability are identified as the key drivers for increase in M&A activities in the global pharmaceutical industry. Larger companies have cash piled in their accounts books, while their product line is limited to few market leading products. These companies find it as an opportunity to acquire and leverage on promising portfolios from smaller organizations.

Buy the report "Global Pharmaceutical Survey 2013-2014 – Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry" at http://www.rnrmarketresearch.com/contacts/purchase?rname=76369; and the report "Global Pharmaceutical Survey 2013-2014 – Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry" at http://www.rnrmarketresearch.com/contacts/purchase?rname=76370.

Reasons to buy one or more of these reports with their key features and benefits:

  • Projects industry trends and revenue growth expectations in 2013, and understand business confidence to make informed business decisions.
  • Drive revenues by understanding future product investment areas and key growth regions.
  • Uncover key challenges and opportunities and identify key actions required to maintain and win buyer business.
  • Formulate effective sales and marketing strategies by identifying the overall size of the marketing budgets of global pharmaceutical industry supplier companies. Also, how buyer budgets are changing and the direction of spending in the future. Better promote your business by aligning your capabilities and business practices with your customer's changing needs.
  • Identifies the key marketing aims of organizations and which sales strategies companies will be adopting to deal with market conditions in 2013-2014.
  • Secure stronger customer relationships by understanding the behaviour and changing strategies of industry buyers.

Explore more reports on the Pharmaceuticals Industry @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals.

About Us:

RnRMarketResearch.com is an online market research reports library of 175,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.

Explore other market reports online as well as Company Profiles and SWOT Analysis Reports of companies in multiple sectors @ http://www.rnrcompanyprofiles.com/popular-companies.

Media Contact: Priyank Tiwari, RnR Market Research, + 1 888 391 5441, sales@rnrmarketresearch.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE RnRMarketResearch
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Actavis Full Year 2012 Net Revenue Increases 29% to $5.91 Billion
2. Medical Marijuana, Inc. Releases 2012 Annual Share Holders Report and First Ever Corporate Revenue Forecasts
3. CryoLife 2012 Annual Revenues Grew to a Record $131.7 Million
4. Cynosure Reports Record Revenues for Fourth-Quarter and Full-Year 2012
5. Mesa Labs Reports 18% Increase in Third Quarter Revenues
6. Perrigo Reports Record Second Quarter Revenue, Adjusted Earnings and Operating Cash Flow
7. Abaxis Reports Record Revenues For The Third Quarter Of Fiscal 2013
8. Haemonetics Reports 3rd Quarter Fiscal 2013 Revenue Up 29% and $0.50 Adjusted EPS; Year-To-Date Organic Revenue Up 3%; Reaffirms Fiscal 2013 Adjusted EPS Guidance of $1.65-$1.70
9. Glenmarks Consolidated Revenue Increases by 33.96% to Rs. 13812.59 Million for Q3 FY 12-13
10. Encision Reports 10% Product Revenue Increase in Third Quarter of Fiscal Year 2013 Results
11. Covance Reports Fourth Quarter Pro Forma Net Revenue Of $561 Million, Pro Forma EPS Of $0.73 And Adjusted Net Orders Of $769 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology:
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
(Date:6/24/2016)... ... ... BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a ... an hour by 2020 and then adjusting it yearly to increase at the same rate ... assure the wage floor does not erode again, and make future increases more predictable. , ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... is proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon ... beautiful women in the world, and the most handsome men, look naturally attractive. ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners ... extensive sequencing and genomics experience, as Vice President of North American Capital Sales at ... responsible for leading the sales team in the commercialization of the HTG EdgeSeq system ...
Breaking Medicine News(10 mins):